Клиномир в тестовом запуске. Кто с нами с первых дней, получит отметку «С первых дней» в профиле и первым увидит новые возможности сайта.

Зарегистрироваться
Завершено Фаза II Россия

Ганаксолон

Многоцентровое двойное слепое рандомизированное плацебо-контролируемое исследование эффективности и безопасности ганаксолона в качестве адъювантной терапии у пациентов с фармакорезистентными парциальными припадками с последующим длительным периодом открытого лечения

Разрешение№ 692 от 01.11.2013
Номер протокола1042-0603
ФазаФаза II
Участников по плану120
Сроки01.11.2013 — 31.07.2017
Страна разработчикаСША
Начало: 1 ноября 2013Окончание: 31 июля 2017
Плановый срок исследования истёк

Постоянная ссылка: https://clinomir.ru/trials/permit/ru/692/2013-11-01/

Источник: ГРЛС — Государственный реестр лекарственных средств Минздрава России; ClinicalTrials.gov (U.S. National Library of Medicine); clinmarket. Что откуда

Простыми словами

Словарь терминов
  • Фаза II — препарат уже прошёл первую проверку безопасности. Проверяют, действует ли он при этом заболевании, и уточняют дозу.
  • Исследование завершено, новых участников не набирают.
  • Возраст участников: от 18 лет. Остальные условия — в блоке «Кто может участвовать».
  • По плану участвуют 120 чел. в стране «Россия».
  • Центров в реестре: 9 в 6 городах. Список — ниже на странице.
  • Плановая дата окончания (07.2017) уже прошла.

Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.

Кто может участвовать

Возрастот 18 лет
ПолЛюбой
Здоровые добровольцынет
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 9 · невключение: 24

Критерии включения

  • Able to give informed consent in writing, or have a legally authorized representative able to do so
  • Willing to enter and participate for the full term of the double blind phase and willing to enter into the open-label phase
  • Male or female outpatients > 18 years of age
  • Have a confident diagnosis of drug-resistant epilepsy with partial-onset seizures (POS), with or without secondary generalization, for ≥2 years. Have residual POS despite having been treated in the past with at least 2 approved anti-epilepsy drugs (AEDs) either alone or in combination
  • Based on history, participants would be anticipated to have at least 3 POS during each 4-week Baseline period and unlikely to have 21 or more consecutive POS-free days
  • Currently being treated and maintained with a stable regimen of 1, 2, or 3 AEDs
  • Able and willing to maintain daily seizure calendar
  • Able and willing to take drug with food twice daily
  • Sexually active women of childbearing potential must use acceptable birth control and have a negative pregnancy test at all visits

Критерии невключения

  • Have had previous exposure to ganaxolone
  • Known sensitivity or allergy to any component in the study drug, progesterone, or other related steroid compounds
  • Exposure to any investigational drug or device <30 days prior to screening, or plans to take another investigational drug at any time during the study
  • Time of onset of epilepsy treatment <2 years prior to enrollment
  • Have generalized epilepsy, such as Lennox-Gastaut syndrome, juvenile myoclonic epilepsy, absence epilepsy, or non-epileptic seizures within the last 12- month period prior to study entry
  • Have less than 3 POS seizures in a 28-day period or more than 21 consecutive seizure-free days during the Baseline period
  • Have only simple partial seizures without any observable motor component
  • Have innumerable seizures or status epilepticus within the last 12-months prior to screening
  • Have more than 100 POS per 4-week Baseline period
  • Have seizures secondary to illicit drug or alcohol use, infection, neoplasm, demyelinating disease, degenerative neurological disease, or central nervous system (CNS) disease deemed progressive, metabolic illness, or progressive degenerative disease
  • Current use of vigabatrin is not permitted. If prior use of vigabatrin, must have documented stable visual fields
  • Current use of ezogabine is not permitted. If prior use, must have been off the medication for at least 3 months prior to screening and have had documented normal fundoscopic exam by ophthalmologist
  • Are planning surgery, or to be evaluated for surgery, during the double-blind phase to control seizures including VNS implantation
  • Are suffering from acute or progressive neurological disease, moderate or severe psychiatric disease, or severe mental abnormalities that are likely to require changes in drug therapy during the double-blind portion of the study or interfere with the objectives of the study or the ability to adhere to the protocol requirements
  • Have a history of an actual suicide attempt in the last 5 years or more than 1 lifetime suicide attempt
  • Have a positive urine drug screen at Screening or meet criteria for current or historical Substance Use Disorder (DSM-V criteria) within the past 5 years.
  • Have any medical condition that, in the investigator's judgment, is considered to be clinically significant and could potentially affect participant safety or study outcome, including but not limited to: clinically significant cardiac, renal, pulmonary, gastrointestinal, hematologic or hepatic conditions; or a condition that affects the absorption, distribution, metabolism or excretion of drugs
  • Have elevated ALT (SGPT) or AST (SGOT) greater than 3 times upper limits of normal, or total bilirubin greater than 1.5 times ULN
  • Have a history of malignancy within the past 2 years, with the exception of basal cell carcinoma
  • Are currently following or planning to follow a ketogenic diet
  • Use of dietary supplements or herbal preparations are not permitted if participant has been using them consistently for less than 6 months prior to screening, or does not plan on remaining on stable doses for the duration of the double blind phase. Use of St. John's Wort is not permitted
  • Females who are pregnant, currently breastfeeding or planning to become pregnant during the duration of the study
  • A history of chronic noncompliance with drug regimens
  • Inability to withhold grapefruit and grapefruit juice from diet during the entire clinical trial

Источник: ClinicalTrials.gov, NCT01963208 · запись обновлена в реестре 14 февраля 2023.

Дизайн и результаты

ДизайнРандомизированное, четверное слепое, параллельные группы; цель — лечение
Включено участников (факт, все страны)405
Что измеряют — первичные конечные точки (1), вторичных — 15
  • Double Blind: Cohort 2: Percent Change From Baseline in 28-day Seizure Frequency During Titration + Maintenance Period — Baseline and Week 14

Цель исследования

The study will evaluate the effectiveness and safety of an investigational drug-ganaxolone - on partial seizure frequency in adults with epilepsy taking a maximum of 3 antiepileptic medications (AEDs).

Области и заболевания

Где проходит

9 центров в 6 городах

Откуда эта информация

Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.

Изменения не сохранены

На этой странице есть несохранённые изменения. Если уйти со страницы, они пропадут.